Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Karonudib in advanced solid tumors
NCT03036228Phase 1Completed
- Sponsor
- Thomas Helleday Foundation
- Start
- Jan 2017
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of karonudib in solid tumor, sponsored by Thomas Helleday Foundation. Primary endpoint: Safety and tolerability of Karonudib at 28 days. Started Jan 2017; status: completed.
02
Drugs
karonudib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03036228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03036228.